Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...